Empirical Financial Services LLC d.b.a. Empirical Wealth Management Buys 1,585 Shares of McKesson Corporation $MCK

Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in McKesson Corporation (NYSE:MCK) by 18.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 10,009 shares of the company’s stock after buying an additional 1,585 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in McKesson were worth $7,732,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. J.W. Cole Advisors Inc. grew its holdings in shares of McKesson by 35.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares in the last quarter. Private Wealth Partners LLC boosted its position in McKesson by 5.6% during the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after purchasing an additional 1,682 shares during the last quarter. AlphaQuest LLC grew its stake in McKesson by 91.2% in the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after purchasing an additional 843 shares in the last quarter. CW Advisors LLC increased its position in shares of McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after purchasing an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in shares of McKesson by 12.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after purchasing an additional 36,451 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. UBS Group boosted their target price on shares of McKesson from $920.00 to $980.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Zacks Research downgraded shares of McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. JPMorgan Chase & Co. upped their target price on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. Finally, TD Cowen boosted their price target on McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, McKesson has an average rating of “Moderate Buy” and a consensus target price of $943.50.

Insiders Place Their Bets

In other McKesson news, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president owned 2,989 shares of the company’s stock, valued at $2,824,605. The trade was a 5.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The disclosure for this sale is available in the SEC filing. Insiders sold 794 shares of company stock worth $718,056 in the last quarter. 0.08% of the stock is currently owned by corporate insiders.

McKesson Stock Performance

Shares of MCK opened at $947.39 on Friday. The firm has a market cap of $116.05 billion, a P/E ratio of 27.25, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40. McKesson Corporation has a 52 week low of $594.34 and a 52 week high of $971.93. The firm’s 50-day simple moving average is $853.65 and its 200 day simple moving average is $795.74.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.